Nathan Rice
Stock Analyst at Piper Sandler
(2.86)
# 1,474
Out of 4,829 analysts
52
Total ratings
45.45%
Success rate
8.26%
Average return
Main Sectors:
Stocks Rated by Nathan Rice
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BFC Bank First | Maintains: Neutral | $110 → $111 | $114.36 | -2.94% | 6 | Apr 17, 2025 | |
| MBIN Merchants Bancorp | Maintains: Overweight | $53 → $57 | $32.55 | +73.58% | 7 | Jan 30, 2025 | |
| FMBH First Mid Bancshares | Maintains: Overweight | $46 → $47 | $37.34 | +25.89% | 3 | Nov 1, 2024 | |
| BY Byline Bancorp | Reiterates: Overweight | $34 | $26.95 | +26.16% | 8 | Oct 29, 2024 | |
| CVS CVS Health | Maintains: Buy | $85 → $74 | $64.81 | +14.18% | 2 | May 2, 2024 | |
| NIC Nicolet Bankshares | Assumes: Neutral | $84 | $122.55 | -31.46% | 1 | Jan 10, 2024 | |
| ALGN Align Technology | Downgrades: Sell | $197 | $189.00 | +4.23% | 10 | Dec 11, 2023 | |
| ELAN Elanco Animal Health | Maintains: Sell | $11 → $9 | $12.82 | -29.80% | 1 | Apr 25, 2023 | |
| IDXX IDEXX Laboratories | Upgrades: Buy | $530 → $435 | $509.53 | -14.63% | 4 | Jul 21, 2022 | |
| CI The Cigna Group | Initiates: Neutral | $233 | $315.74 | -26.21% | 5 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $83 | $62.87 | +32.02% | 4 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $17.09 | -12.23% | 1 | Dec 19, 2019 |
Bank First
Apr 17, 2025
Maintains: Neutral
Price Target: $110 → $111
Current: $114.36
Upside: -2.94%
Merchants Bancorp
Jan 30, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $32.55
Upside: +73.58%
First Mid Bancshares
Nov 1, 2024
Maintains: Overweight
Price Target: $46 → $47
Current: $37.34
Upside: +25.89%
Byline Bancorp
Oct 29, 2024
Reiterates: Overweight
Price Target: $34
Current: $26.95
Upside: +26.16%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85 → $74
Current: $64.81
Upside: +14.18%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $122.55
Upside: -31.46%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $189.00
Upside: +4.23%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11 → $9
Current: $12.82
Upside: -29.80%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530 → $435
Current: $509.53
Upside: -14.63%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $315.74
Upside: -26.21%
Dec 14, 2021
Initiates: Neutral
Price Target: $83
Current: $62.87
Upside: +32.02%
Dec 19, 2019
Initiates: Overweight
Price Target: $15
Current: $17.09
Upside: -12.23%